Nurix Therapeutics (NRIX) | Stock Overview & Key Data
Nurix Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $8.33
High: $8.68
on September 16, 2025
52 Week Range
Low: $8.18
High: $29.56
on April 10, 2025
on November 11, 2024
All-Time High: $52.38 on December 14, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$684.2M
EPS
-2.60
P/E Ratio (TTM)
-3.11
Forward P/E
-3.31
P/B Ratio
1.57
PEG Ratio
0.12
Div. Yield
N/A
ROE
-50.67%
Beta
2.100
Debt to Equity
11.60
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-109.68%
Profit Margin
-234.57%
Returns and Earnings
Return on Assets (TTM)
-26.13%
Return on Equity (TTM)
-50.67%
EBITDA
$-222.2M
Net Income (TTM)
$-207.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.16
Quarterly Revenue Growth (YoY)
264.30%
Quarterly Earnings Growth (YoY)
264.34%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics NRIX | 684.22M Small-cap | -10.62% | -18.05% | -27.20% | -37.76% | -55.56% | -66.16% | -30.81% | -71.74% |
| Vertex VRTX | 101.15B Large-cap | -0.52% | 0.11% | -12.80% | -23.46% | -3.09% | -15.42% | 38.72% | 46.62% |
| Alnylam ALNY | 60.45B Large-cap | 1.34% | 2.72% | 49.34% | 82.19% | 97.39% | 68.37% | 129.67% | 233.41% |
| Recursion RXRX | 2.11B Mid-cap | 3.25% | -17.33% | -4.60% | -30.26% | -33.84% | -29.85% | -55.79% | -84.76% |
| Adaptive ADPT | 1.92B Small-cap | 4.31% | 0.31% | 27.11% | 73.47% | 111.31% | 181.29% | 101.23% | -72.91% |
| Harmony Biosciences HRMY | 1.86B Small-cap | -9.29% | -11.85% | -1.22% | -5.30% | -6.69% | -17.28% | -23.48% | -3.87% |
Ownership & Short Interest
Insider Ownership
1.43%
Institutional Ownership
115.02%
Shares Short
13M
Short Ratio
18.20
Short % of Shares Outstanding
19.79%
Average 10-Day Volume
853K
Average 90-Day Volume
741K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NRIX's 52-week high and low?
- In the last 52 weeks, Nurix Therapeutics reached a high of $29.56 (on November 11, 2024) and a low of $8.18 (on April 10, 2025).
- What is the market cap and P/E ratio for NRIX?
- Curious about Nurix Therapeutics's size and valuation? Its market capitalization stands at 684.22M. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.11, and the forward P/E (looking ahead) is -3.31.
- Does NRIX pay dividends? If so, what's the yield?
- As for dividends, Nurix Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nurix Therapeutics's main competitors or similar companies to consider before investing?
When looking at Nurix Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.15B Healthcare Biotechnology -15.42% 38.72% Alnylam
ALNY60.45B Healthcare Biotechnology 68.37% 129.67% Recursion
RXRX2.11B Healthcare Biotechnology -29.85% -55.79% Adaptive
ADPT1.92B Healthcare Biotechnology 181.29% 101.23% Harmony Biosciences
HRMY1.86B Healthcare Biotechnology -17.28% -23.48% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nurix Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Nurix Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -50.67%, the Debt to Equity ratio from the most recent quarter is 11.60, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NRIX?
- Looking at Nurix Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $88M. Compared to the same quarter last year (YoY), quarterly revenue grew by 264.30%, and quarterly earnings saw a YoY growth of 264.34%.
- How much of NRIX stock is held by insiders and institutions?
- Wondering who owns Nurix Therapeutics stock? Company insiders (like executives and directors) hold about 1.43% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 115.02%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.